AIDS treatment device

Abstract

An HIV (human immunodeficiency virus) therapeutic apparatus for the field of medical science is characterized in that a separator capable of separating blood cells and plasma is prepared, HIV gp120 and gp41 antibodies and HIV gp120 and gp41 antibodies capable of combining anti-goat Ig are prepared, CD4+T cell lines and hybrid tumor macrophage cell lines retaining myogenic cell properties and capable of infinitely growing are built by exogenous gene transfection and hybridoma technology respectively, the cell lines are amplified and then distributed in agar gel, the agar gel is wrapped by high-biocompatibility materials to prepare a purifier, the gel forms layering distribution of antibody titer from high to low and agarose concentration from low to high from top to bottom, anti-goat Ig combined and free gp120 and gp41 antibodies, the CD4+T cell lines and the hybrid tumor macrophage cell lines are fixed to the agar gel to function in adsorbing HIV, the prepared purifier is combined with the separator and a control procedure in use, blood in extracorporeal circulation is divided into the plasma and the blood cells by the separator, the HIV in the plasma is filtered by the purifier, and then the plasma is converged with the blood cells and returned.

Description

technical field [0001] The invention relates to the preparation and application of an AIDS treatment instrument in the medical field, which is mainly used for the removal of plasma HIV from AIDS patients so as to achieve the purpose of treating AIDS. Background technique [0002] After HIV enters the human body, it is first swallowed by macrophages, but HIV quickly changes the acidic environment in certain parts of the macrophages and creates conditions suitable for its survival. Instead of being killed, HIV reproduces in them. Because CD4 is the receptor of HIV, the HIV that propagates in the macrophage passes through its envelope protein gp120 and with the help of gp41 (gp41 acts as a bridge, using its own hydrophobicity to mediate the fusion of the viral envelope and the cell membrane ) into CD4+ cells (cells, mononuclear macrophages, dendritic cells, etc.), proliferate rapidly in the cells, and produce 10 9 ~10 10 Virus particles, and continuously enter other normal an...

AI Technical Summary

Problems solved by technology

However, the antibody cannot contact the virus remaining in the mononuclear macrophage, and the HIV envelope protein is prone to antigenic variation, and the original antibody loses its effect, so that the neutralizing antibody cannot play its due role

During the latent infection stage, the HIV provirus is integrated into the host cell genome, so HIV will not be recognized by the immune system, so it cannot be eliminated by autoimmunity alone

Another very important reason should be that, based on the mechanism of antibody killing and clearing antigens, it is speculated that after the immune antibody binds to the antigen, it will produce an immune effect, or it will mediate the ADCC effect to dissolve the cellular antigen by activating complement, but HIV does not Cellular antigens; either attract phagocytes to phagocytize and clear antigens through chemotaxis, but HIV is protected and proliferated in phagocytes instead; or antibodies combine with antigens to neutralize and make them lose their infectivity, but the structure of HIV antigens is variable , often making it difficult for antibodies to recognize

[0004] Judging from the current AIDS treatment methods that have been used clinically, the effect is not so ideal: (1) HIV reverse transcriptase inhibitors: can only prevent the infection of susceptible cells that have not been infected with HIV, and have no therapeutic effect on infected cells, and are toxic There are many side effects, including mitochondrial toxicity, myelosuppression, erythrocytic anemia, neutropenia and thrombocytopenia, pancreatitis, and the generation of cross-drug resistance. Drug-resistant variants, resulting in decreased clinical efficacy or failure

(2) HIV protease inhibitors: prone to drug-induced liver injury, lipid metabolism disorders and other side effects and drug resistance

(4) Inhibiting HIV virus entry inhibitors: including blocking the binding of gp120 to CD4, blocking the binding of HIV to coreceptors, acting on gp41 membrane subunits, and acting on CC chemokine receptor 5 (CCR5) on the surface of T lymphocytes to block HIV from entering host cells, but has side effects on the liver and heart

(6) HIV vaccine treatment: Due to the particularity of HIV, such as innate immunity is not enough to resist HIV and its targeted destruction of the immune system, and the virus mutates rapidly, so far no truly safe and effective vaccine has been developed

(7) Gene therapy: HIV gene therapy research has never stopped, including antisense technology, RNA decoy, RNA interference, intracellular antibodies, dominant negative mutants, suicide genes, etc., but gene therapy that has entered phase II clinical trials hardly

[0008] In short, various drugs and biological products cannot effectively kill HIV in the body, and they are expensive and have severe side effects. So far, there is no effective method for the treatment of AIDS, which has become a worldwide problem that cannot be overcome for a long time.

Images